Gastrointestinal Stromal Tumor (GIST)

What GIST is — in plain words

GIST stands for gastrointestinal stromal tumor. It is the most common mesenchymal cancer of the digestive tract — meaning it does not start from the lining of the gut (the way stomach or colon cancers do), but from a small specialised group of cells in the gut wall called the interstitial cells of Cajal. These cells act like the pacemakers of the digestive system, coordinating its rhythmic squeezing.

Because GIST grows inside the wall of the bowel rather than on its inner surface, it can become surprisingly large before it causes any symptoms — and it often turns up by accident on a scan done for another reason.

Where in the gut GIST tends to appear

Who tends to develop it

GIST is uncommon. It is mostly diagnosed in adults between 50 and 70, equally in men and women. A small number of cases are familial — often associated with specific inherited KIT or PDGFRA mutations, with neurofibromatosis type 1, or with the rare Carney triad in younger patients. The great majority of cases, however, are sporadic, with no identifiable family link and no clear external cause.

Signs and symptoms to take seriously

GIST often whispers before it shouts. Many patients have very few symptoms; others present quite dramatically when the tumour bleeds or grows large enough to press on neighbouring organs.

Iron-deficiency anaemia in an adult with no obvious explanation is always worth investigating, and a GIST is one of the diagnoses that occasionally turns up at the end of that workup.

"Two decades ago, GIST was a sentence. Today, in clinic, I have patients I have been treating for twelve, fifteen years — on a tablet, working, travelling, with grandchildren. The disease has not gone away; it has been turned into something they live alongside. That is what good medicine can do."

How GIST is diagnosed

The diagnosis usually unfolds in three stages: finding the lump, sampling it, and reading its molecular features.

• Imaging — a CT scan of the abdomen and pelvis with contrast shows where the tumour is, how big it is, and whether it has spread (most commonly to the liver, or as deposits on the lining of the abdomen).
• Endoscopy — for stomach or duodenal tumours, an upper endoscopy can see the bulge from the inside. Endoscopic ultrasound (EUS) measures the depth of the tumour in the bowel wall and can guide a biopsy.
• Biopsy — a tissue sample is essential before any non-surgical treatment is given. For small, easily resectable tumours, the biopsy may be the surgical specimen itself; for larger or metastatic tumours, an EUS-guided biopsy is the preferred route.
• Pathology and immunohistochemistry — the lab confirms the diagnosis by staining for KIT (CD117), DOG1 and CD34. Almost all GISTs are positive for KIT and DOG1 — together they make the diagnosis very secure.
• Molecular (mutation) testing — perhaps the single most important test in modern GIST care. About 80% of GISTs carry an activating mutation in the KIT gene, and another 10% in PDGFRA. The specific mutation (which exon, which codon) directly predicts which targeted drug will work — and which will not.

The biology that changed everything

For most of the twentieth century, GIST was treated as a stubborn, chemotherapy-resistant sarcoma — and outcomes were poor. The breakthrough came in the late 1990s, when researchers showed that the engine driving the cancer was a constantly switched-on KIT or PDGFRA receptor. A drug already being developed for chronic myeloid leukaemia — imatinib (Gleevec) — happened to switch that engine off.

The first patient treated with imatinib for advanced GIST, in 2000, had a near-complete response within weeks. Within a few years, imatinib had transformed median survival in advanced GIST from about a year to many years. It is one of the cleanest, most decisive successes of targeted cancer therapy in history.

How GIST is treated

The treatment depends on whether the tumour is localised (still confined to the gut wall, removable with surgery) or has spread. Either way, the plan is built by a team — a medical oncologist, a surgeon experienced in gastrointestinal cancers, a pathologist, a radiologist, and where appropriate an endoscopist.

Surgery for localised disease

For a GIST that has not spread, complete surgical removal is the goal — and for most patients it is curative on its own. The surgeon aims to remove the tumour with a clear margin, but without the extensive lymph node dissection that other gut cancers need (GIST very rarely spreads through lymph nodes). For small stomach GISTs, a wedge resection is often enough; larger or awkwardly placed tumours may need more.

Risk assessment after surgery

Once the tumour is in the lab, the pathologist measures three things that together predict the risk of recurrence: the size of the tumour, the number of dividing cells (mitotic rate), and the site (stomach is generally lower risk than small bowel). The mutation result is added to this. From these we place each patient into a risk group — very low, low, intermediate or high.

Adjuvant imatinib

For high-risk patients after surgery, three years of daily imatinib substantially lowers the chance of the cancer coming back, and improves long-term survival. Some patients with particularly high-risk features stay on it for longer. Patients whose tumour carries certain mutations (notably PDGFRA D842V) do not benefit from imatinib and are not given it.

Treatment of advanced or metastatic GIST

Even when GIST has spread — usually to the liver or to the lining of the abdomen — it is highly treatable. Targeted tablets are the mainstay, used in a careful sequence:

Surgery can still have a role in advanced GIST — for example, removing a single area that has become resistant while the rest of the disease remains controlled. That kind of judgement is made in a multidisciplinary discussion.

What the outlook honestly looks like

For a localised GIST removed completely with surgery, the outlook is excellent — most patients in the low- and very-low-risk groups are cured by the operation alone. For higher-risk patients, three years of adjuvant imatinib lifts the long-term cure rate considerably further.

For advanced or metastatic GIST, the goal shifts from cure to durable control — and the targeted tablets achieve that remarkably well. Median survival has gone from roughly a year before imatinib to many years today, and a meaningful number of patients are living a decade or more with the disease quietly controlled.

Numbers are averages. The specific mutation, the response to the first drug, and your general fitness all influence what happens next. We will be honest with you about the realistic range, and we will revisit it as the situation evolves.

Life during treatment

Imatinib is a tablet taken once a day, ideally with food. Most patients work, travel and live a normal life on it. Common side effects include mild swelling around the eyes, fatigue in the first weeks, occasional nausea, muscle cramps and a faint rash. Blood counts and liver function need a check every few months. Stronger side effects are uncommon and almost always settle with dose adjustment.

Drug interactions matter — please tell us about every tablet you take, including herbal remedies. Paracetamol is fine; some other medicines need to be timed differently. Pregnancy should be avoided during imatinib, and women of child-bearing age should discuss contraception openly with the team.

Follow-up

After surgery for localised disease, follow-up is typically a CT scan every three to six months for the first few years, then less often. On long-term imatinib for advanced disease, scans are done regularly to confirm the disease is staying quiet. Most of the visit time, though, is spent on how you feel — energy, appetite, side effects, mood. Those things tell us as much as the scans do.

Why this disease is a story of hope

Twenty-five years ago, a diagnosis of advanced GIST meant a few short months. Today the same diagnosis means a long, careful conversation about which tablet, in which order, for which mutation — and most patients leaving that conversation can expect years, often many years, of life ahead. The science of GIST is the clearest proof we have that finding the precise molecular switch driving a cancer, and turning it off, can change everything.